M-M-RvaxPro

Sanofi Pasteur MSD are replacing their M-M-R II vaccine with the M-M-RvaxPro.

The formulation and new vial and pre-filled syringe presentation of M-M-RvaxPro is different from M-M-R II, but the new vaccine contains the same three virus strains and has similar immunogenicity and safety to M-M-R II.

Further information: Sanofi Pasteur MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Avoid benzodiazepines in opioid-dependent patients, GPs reminded

Avoid benzodiazepines in opioid-dependent patients, GPs reminded

Prescribing benzodiazepines in opioid-dependent individuals...

Flu antivirals approved for NHS prescribing as cases increase

Flu antivirals approved for NHS prescribing as cases increase

GPs can now prescribe antiviral medicines for flu prophylaxis...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

New e-cigarette alternative launched on prescription

New e-cigarette alternative launched on prescription

Voke, a new nicotine inhaler, is available to prescribe...